Bruton tyrosine kinase inhibitors for multiple sclerosis

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Current multiple sclerosis (MS) therapies primarily target peripheral immune cell infiltration into the central nervous system (CNS), with limited efficacy in slowing progressive disability.
• CNS-compartmentalized inflammation, driven by B cells and microglia, is increasingly recognized as a key factor in MS disability accumulation.

Purpose of the Study:

• To review the role of Bruton tyrosine kinase (BTK) in MS immunopathogenesis.
• To summarize preclinical and clinical data on BTK inhibitors as a potential treatment for MS.

Main Methods:

• Literature review of BTK's function in immune cells relevant to MS.
• Analysis of preclinical studies investigating BTK inhibitors.
• Discussion of preliminary clinical trial data for BTK inhibitors in MS.

Main Results:

• BTK is crucial for B cell and microglia function, both implicated in MS.
• CNS-penetrant BTK inhibitors may target inflammation within the CNS, potentially impacting disease progression.
• Five distinct BTK inhibitors are in clinical trials for MS.

Conclusions:

• BTK inhibitors represent a novel therapeutic strategy for MS, potentially addressing CNS-compartmentalized inflammation.
• Targeting BTK may offer a more effective approach to slowing disability accumulation in progressive MS.
• Further clinical evaluation is necessary to establish the efficacy and safety of BTK inhibitors in MS treatment.